First human gene therapy trial in Huntington’s disease
Huntingtin-lowering The focus of the first trial is safety and tolerability – finding out whether there any harmful or unpleasant effects of receivingRead more.
Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s
Wave and Roche neck and neck! This is very good news for Huntingtonians world-wide! We attended a very exciting webcastRead more.
Update from Stronger together, better together conference
“Strange strategy from Roche!” Svein Olaf Olsen- President of the International Huntington Association The President of The International Huntington AssociationRead more.
Update: RG6042 Phase III GENERATION HD1 study re-opens
Dear global patient community partners, Following your previous request to be kept up to date on the clinical development programmeRead more.
The inaugural conference of Huntington Disease Society of India
This picture was taken at the Inaugural conference of Huntington Disease Society of India. Among others, Svein Olaf Olsen –Read more.